Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.

Breast (Edinburgh, Scotland) - 1 Jun 2023

Blancas Isabel, Linares-Rodríguez Marina, Martínez de Dueñas Eduardo, Herrero-Vicent Carmen, Molero-Mir María D, Garrido José M, Rodríguez-Serrano Fernando

Abstract excerpt

PURPOSE: Tamoxifen is a drug used for hormone receptor-positive breast cancers, primarily metabolised by the CYP2D6 enzyme into active metabolites such as endoxifen. CYP2D6 displays varying degrees of activity depending on its genotype. This study aims to analyse the effect of an early increase in tamoxifen dose in poor metabolisers (PM) on survival. METHODS: We enrolled 220 patients diagnosed with breast cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Propensity Score

Share to Tamoxifen

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 37011481
DOI: 10.1016/j.breast.2023.03.012
PMCID: PMC10090803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.PMID 37011481Read ↗

Tamoxifen Dose Escalation in CYP2D6 Poor Metabolizer Breast Cancer Patients and Associated Side EffectsSemantic proximity Read ↗

Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.Semantic proximity Read ↗

No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.Semantic proximity Read ↗

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.Semantic proximity Read ↗

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a ControversySemantic proximity Read ↗

Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Semantic proximity Read ↗

Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?Semantic proximity Read ↗

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.Semantic proximity Read ↗

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.